Chauhan Manoj Kumar Hariram, Jha Ashish Kumar, Mithun Sneha, Parab Rutuja Dasharath, Dwivedi Pooja, Puranik Ameya D, Gala Kunal Bharat, Shetye Nitin Sudhakar, Kulkarni Suyash, Rangarajan Venkatesh
Department of Nuclear Medicine and Molecular Imaging, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Mumbai, Maharashtra, India.
Department of Radiology, Tata Memorial Centre, Tata Memorial Hospital, Mumbai, Maharashtra, India.
Indian J Nucl Med. 2024 Jul-Aug;39(4):254-258. doi: 10.4103/ijnm.ijnm_88_23. Epub 2024 Nov 18.
Lu-DOTATATE peptide receptor therapy (PRRT) is an established treatment for patients suffering from neuroendocrine tumors. In the last few years, intra-arterial PRRT is being considered for patients having liver metastatic disease predominantly. The aim of our study is to measure the radiation doses received by the treating intervention radiologists involved in intra-arterial PRRT treatment using Lu-DOTATATE.
Radiation safety-related data of 31 patients who underwent 177Lu-DOTATATE intra-arterial PRRT treatment were used for this study. The exposure rate was measured at the hand and eye and chest level of treating intervention radiologists continuously from the beginning to the end of the administration. Exposure from the patient at the body surface (at the level of liver, thigh, and extremities) and 1 m from the body surface was measured just after the administration. The mean radiation exposure from the patient at the body surface and 1 m from the body was also calculated.
The mean administered activity was found to be 194 (±17) mCi. The mean radiation exposure at the surface at the level of the liver, thigh, and feet and at 1 m from the surface was found to be 100 (±25.11), 9 (±1.27), 5.6 (±0.52), and 5.3± (0.50) μSv/hr, respectively. The mean administration time was found to be 23 ± 5.6 min. The mean radiation dose to the hands, and eyes, of the treating intervention radiologist per procedure, was found to be 6.425 ± 2.75 μSv, 5.43 ± 1.76 μSv and 1-m exposure from the patient was found to be 5.3 ± 0.246 μSv, respectively.
Our result shows that the radiation exposure from the patient postadministration is below the permissible limit of discharge. The radiation exposure to the intervention radiologist is also suggestive of a safe procedure to be performed by maintaining the radiation dose well within the permissible limit for radiation professionals.
镥-多柔比星肽受体治疗（PRRT）是治疗神经内分泌肿瘤患者的一种既定疗法。在过去几年中，主要针对患有肝转移疾病的患者考虑采用动脉内PRRT。我们研究的目的是测量参与使用镥-多柔比星进行动脉内PRRT治疗的介入放射科医生所接受的辐射剂量。
本研究使用了31例接受177Lu-多柔比星动脉内PRRT治疗患者的辐射安全相关数据。从给药开始到结束，持续测量治疗介入放射科医生手部、眼部和胸部水平的照射率。给药后立即测量患者体表（肝脏、大腿和四肢水平）以及距体表1米处的辐射。还计算了患者体表和距体表1米处的平均辐射暴露量。
发现平均给药活度为194（±17）毫居里。发现肝脏、大腿和足部水平的体表以及距体表1米处的平均辐射暴露量分别为100（±25.1）、9（±1.27）、5.6（± .52）和5.3±（0.50）微希沃特/小时。发现平均给药时间为23±5.6分钟。发现每次治疗过程中，治疗介入放射科医生手部和眼部的平均辐射剂量分别为6.425±2.75微希沃特、5.43±1.76微希沃特，且患者1米处的辐射暴露量为5.3±0.246微希沃特。
我们的结果表明，给药后患者的辐射暴露低于允许的排放限值。介入放射科医生的辐射暴露也表明，通过将辐射剂量保持在辐射专业人员允许的限值内，可以安全地进行该操作。
